- In acute migraine, vs placebo, 75 mg rimegepant yielded significantly greater pain relief/freedom from the most bothersome migraine symptoms within 2 hours of treatment.
- The pain relief persisted at 48 hours after treatment.
- Adverse event rates were similar.
Why this matters
- Recent studies of rimegepant yielded conflicting results about efficacy and tolerability.
- A meta-analysis of 4 RCTs involving 3827 patients.
- Outcomes: freedom from pain and most bothersome symptom; pain relief at 2 hours.
- Funding: Suzhou Health Talents Training Project.
- At 2 hours, rimegepant (75 mg) vs placebo had significantly higher:
- Freedom from pain: 20.6% vs 12.5% (relative risk [RR], 1.70; P<.001>
- Pain relief: 58.6% vs 44.6% (RR, 1.34; P<.001>
- Freedom from most bothersome symptoms: 36.0% vs 25.1% (RR, 1.44; P<.001>
- Photophobia: 35.5% vs 23.9% (RR, 1.49; P<.001>
- Phonophobia: 40.1% vs 29.1% (RR, 1.41; P<.001>
- Nausea (P=.105).
- Urinary tract infection (P=.144).
- Dizziness (P=.781).
- No serious AEs identified.
- No comparison with other drugs.